Datapoint: Rigel’s New AML Drug Will Face Off Against Tibsovo

The FDA last week approved Rigel Pharmaceuticals’ Rezlidhia for the treatment of relapsed or refractory acute myeloid leukemia (AML) with the IDH1 mutation in adult patients. The drugmaker in August paid just $2 million to Forma Therapeutics for Rezlidhia’s exclusive licensing rights. The approval means Rezlidhia will go head-to-head with Servier’s Tibsovo, which scored a nod for IDH1-mutated AML in May. For the treatment of AML, Tibsovo currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. About 29% of insured lives have preferred access to Tibsovo, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 12/5/22

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today